Lead sponsor
Jiangsu Hansoh Pharmaceutical Co., Ltd.
17 GLP-1 and incretin trials led. Source: ClinicalTrials.gov, as of July 6, 2026.
17
Trials led
3
Ongoing
3,274
Total enrollment
14
Sites
Distinct sites across this sponsor's lead trials. A site running several of them counts once, matching the map. Total enrollment sums each trial's reported enrollment, whether planned or actual.
Portfolio
How this sponsor's trials break down
Trials by phase
Phase 1
9
Phase 2
3
Phase 3
5
Trials by status
Not yet recruiting
2
Recruiting
1
Completed
9
Unknown
5
Trials led
TrialEligibility highlightPhaseStatusEnrollment
Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminBMI 20-40Ph 3Unknown587
Efficacy and Safety Study of PEX168 in Monotherapy Diabetes Mellitus Type 2 PatientsBMI 20-40Ph 3Unknown406
A Phase 3 Study of HS-20094 in Patients With T2DM Inadequately Controlled With Diet and Exercise AloneHbA1c ≤10.5%Ph 3Not yet recruiting204
A Study of HS-20094 Evaluating Weight Loss in Obese and Overweight Chinese SubjectsBMI ≥28Ph 2Completed200
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HS-20004 in Healthy Chinese VolunteersBMI 19-24Ph 1Completed62
Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple s.c Doses HS-20004 in Healthy Chinese VolunteersBMI 19-28Ph 1Completed40
Polyethylene Glycol Loxenatide Pharmacokinetics Study in Subjects With Normal and Insufficiency Renal FunctionBMI ≤28Ph 1Unknown24
Evaluate the Pharmacokinetics of Simvastatin When Coadministered With PEX168 in Healthy Adult SubjectsBMI 18-25Ph 1Completed16
Evaluate the Pharmacokinetics of Digoxin When Coadministered With PEX168 in Healthy Adult SubjectsBMI 18-25Ph 1Completed16
Evaluate the Pharmacokinetics of Warfarin When Coadministered With PEX168 in Healthy Adult SubjectsBMI 18-25Ph 1Completed16
Tolerability to HS-20004 With Titration Administration in Type 2 Diabetic PatientsBMI 18.5-30Ph 1Unknown12